Decoding Cancer Clinical Trials: Why Participation Matters More Than You Think
"Exploring the motivations and barriers behind patient participation in cancer research—and how understanding them can improve outcomes for everyone."
In the ongoing battle against cancer, clinical trials stand as a beacon of hope and a cornerstone of medical progress. These trials, which evaluate the safety and effectiveness of new treatments, rely heavily on the participation of individuals diagnosed with cancer. Despite their critical role, a surprisingly small percentage of patients—estimated between 3% and 5%—actually participate. This limited participation presents a significant obstacle to advancing cancer care and improving patient outcomes.
Why is participation so low, and what can be done to encourage greater involvement? Research suggests that the decision to participate (or not) is influenced by a complex interplay of psychological, social, and practical factors. Understanding these factors is essential not only for researchers and healthcare providers, but also for patients and their families as they navigate treatment options.
This article delves into the multifaceted world of cancer clinical trials, exploring the motivations that drive participation, the barriers that hinder it, and the potential for increasing involvement through targeted strategies. By examining the decision-making processes of both patients and oncologists, we aim to shed light on this critical area of cancer research and pave the way for a more inclusive and effective approach to fighting this disease.
Trial Numbers Are Growing, But So Is the Pressure
Every registered interventional study receives a unique ClinicalTrials.gov identifier—an NCT number—that makes each trial trackable in a global registry. That registry's reach is expanding: one education report found that the number of clinical trials in low- and middle-income countries increased by 35% between 2018 and 2022. Even so, research operations face real pressure, with roughly 12,313 active FDA investigational new drug applications keeping regulatory timelines tight and 67% of sponsors reporting faster, improved recruitment after adding electronic consent capabilities. Institutions are responding—Memorial Sloan Kettering, which incubates and implements better ways to run clinical trials, reports an adjusted survival rate for all cancers combined, based on Medicare patient data, when compared to all NCI-Designated Comprehensive Cancer Centers.
The Limits of the Traditional Randomized Trial
The randomized controlled trial remains the backbone of cancer drug development, but researchers increasingly question whether it fits every question. Complex and often overly restrictive eligibility criteria have created substantial barriers to patient access to novel therapies, hindered trial recruitment and completion, and limited the generalizability of results—prompting a LUNGevity Foundation working group to develop a framework for lung cancer trial eligibility criteria. The rapid expansion of therapeutic modalities and combinations is also challenging the traditional approach, threatening to render it inadequate, inefficient, or even obsolete in some settings. In response, trialists distinguish explanatory designs, well-suited to novel agents with limited safety data, from pragmatic methodology that compares treatments against standard of care in real-world conditions.
From Exclusion to Inclusion in Trial History
Clinical trials are research studies that test how well new medical approaches work in people, answering scientific questions to find better ways to prevent, screen for, diagnose, or treat disease. Yet participation has not always been open to everyone: women were historically underrepresented in trials, and were not generally considered for participation until the 1990s, shaped by institutional bias and concerns about how trials could affect fertility. Patient accounts capture how far the field has come—a man treated at UC San Diego Health described how an innovative prostate cancer clinical trial saved his life. Today, searchable registries let patients worldwide find studies by cancer type, treatment, mutation, phase, and country.
The Psychology of Participation: Motivations and Barriers
The decision to participate in a cancer clinical trial is rarely a straightforward one. Patients weigh a variety of factors, including potential benefits, risks, personal beliefs, and social influences. These considerations can be broadly categorized as:
- Egoistic Motives: Self-interest often plays a significant role. Patients may hope to gain access to cutting-edge treatments, receive closer medical monitoring, or improve their own chances of survival. The perceived costs and benefits of participation are carefully weighed.
- Trust and Relationships: The relationship between a patient and their oncologist is a crucial factor. Patients who trust their doctor and feel supported are more likely to participate. Conversely, distrust or communication barriers can deter involvement.
- Practical Considerations: Logistical challenges, such as travel, time commitments, and financial burdens, can also impact the decision. Patients may struggle to balance trial participation with work, family responsibilities, and other obligations.
New Tools and Therapies Keep Trials in Motion
New developments are broadening both the reach and the accessibility of cancer research. Recent reporting highlights an upcoming US FDA advisory meeting to review Grail's multi-cancer detection test, a sign of the growing push toward earlier, broader cancer screening. Patient-facing tools such as an interactive quiz now help people decide whether a clinical trial fits into their treatment plan. Personal stories reinforce what is at stake: an acute myeloid leukemia survivor described how a clinical trial based on cutting-edge preclinical research pioneered by Michael Andreeff, M.D., put her cancer back into remission, until a CT scan in August 2013 detected leukemia in her brain.
When Treatment Is Sought Outside the Trial System
Not every treatment patients turn to has been tested the way conventional drugs are. Fenbendazole, an anthelmintic, has been self-administered by some cancer patients as a therapy, as documented in case studies. The available reporting stresses that the drug lacks regulatory approval and has not undergone extensive clinical trials as a cancer treatment in humans. Because the evidence rests on isolated case studies rather than large controlled trials, this example highlights the gap between patient enthusiasm and scientifically established benefit.
Head-to-Head Trials Answer the Hard Questions
Head-to-head comparisons give patients and doctors direct evidence about which approach works better. A Phase III study set out to compare the efficacy and tolerance of sequential versus alternate front-line administration of cisplatin-etoposide and topotecan in patients with extensive-stage small cell lung cancer. Likewise, an open-label Phase 3 study is comparing the investigational agent MK-5684 against alternative abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer previously treated with next-generation hormonal therapy. Comparative work is even reaching into alternative treatments, as seen in a 2026 prospective observational study of ivermectin plus mebendazole in cancer patients—though a critical evidence review notes that mainstream guides to "alternative" cancer treatments, including a widely cited Mayo Clinic overview, present a more cautious picture.
Moving Forward: Strategies for Increasing Participation
Addressing the issue of low participation rates in cancer clinical trials requires a multifaceted approach that targets both patient and physician behavior. Some potential strategies include: Improving Communication: Oncologists should engage in open and transparent conversations with patients about clinical trials, addressing their concerns and providing clear, unbiased information. Tailoring information to individual needs and cultural backgrounds is essential.
An Urgent Message: Trials Need Patients
Experts deliver a consistent and urgent message: clinical trials need cancer patients. A cancer clinical trial is a research study that uses volunteers to help doctors discover better ways to diagnose, prevent, or fight cancer—and every trial depends on those volunteers. A shortage of participants significantly increases the time it takes for new medications and treatments to be approved, because trials take so much longer to complete. The demand for participation is visible at scale, including a breast cancer screening trial involving AI that is set to enroll 700,000 women, with experts such as Katrina Pedersen, M.D., speaking to how such studies improve patient outcomes.
Smarter Drugs, Closer Trials
Future therapies are being designed to close treatment gaps. In HER2-targeted therapy, experts are exploring next-generation antibody-drug conjugates, bispecific antibodies, and HER3-targeted drugs, with ongoing clinical trials aiming to extend benefits into HER2-low and resistant populations. Where those trials take place is changing too: a Mayo Clinic study found that bringing clinical trials closer to patients expands access to research. As Tufia Haddad, M.D., a medical oncologist at Mayo Clinic Comprehensive Cancer Center, puts it, "Clinical trials shape the future of medicine."
The Systemic Roadblocks Behind Low Enrollment
Low participation is not primarily a matter of patient willingness—it reflects systemic constraints. As one oncologist explains, limitations exist at many levels, beginning with the systemic and structural: trial availability is limited, so the number of trials open for a given cancer and stage, and which hospitals offer them, determines who can enroll. That is the roadblock that keeps most cancer patients from joining clinical trials, even though trials represent the pinnacle of medical progress, turning today's research into tomorrow's standard of care. Removing these structural barriers would expand access to cutting-edge treatments before they become widely available.
Real-World Patients, Real-World Evidence
Real-world data are beginning to show which patients benefit most once therapies leave the controlled trial setting. A retrospective study reported valuable real-world information on clinical outcomes for patients from underrepresented racial/ethnic groups undergoing immunotherapy for metastatic non-small cell lung cancer, a population that has historically been underrepresented in lung cancer trials. The human side of research also shows in the teams behind the studies: a Mayo Clinic clinical trials team is working to test a screening tool for colorectal cancer, a leading cause of cancer deaths in the U.S., describing trials as a beacon of hope. Meanwhile, centers such as Memorial Sloan Kettering continue to run Phase 3 randomized, double-blind trials of novel agents, underscoring the breadth of ongoing work.